期刊文献+

人血浆中去甲万古霉素质量的HPLC法检测 被引量:1

Determination of Norvancomycin in Human Blood Plasma by HPLC
原文传递
导出
摘要 目的:建立内标法测定人血浆中去甲万古霉素质量的HPLC检测方法。方法:采用20%(200mg/mL)硫酸锌溶液直接沉淀血浆蛋白,以万古霉素为内标,HPLC法测定人血浆中去甲万古霉素的质量。结果:人血浆中杂质不干扰样品峰和内标峰,在低浓度(2.00μg/mL)、中浓度(20.00μg/mL)、高浓度(200.00μg/mL)的回收率分别为90.50%,93.70%和96.40%;批内精密度3种(低、中、高)浓度分别为8.50%,6.40%和5.30%,批间精密度分别为9.40%,7.50%和6.70%,最低检测限为0.50μg/mL,线性范围为1.00-300.00μg/mL。结论:本法稳定、便捷、精密度好,准确可靠,适用于去甲万古霉素血药浓度测定。 Objective: To establish the determination of norvancomycin in human blood plasma by HPLC.Methods: Plasma protein was precipitated with zinc sulfate Solution(20.00% or 200 mg/mL),and vancomycin was used as internal standard.Plasma concentrations of norvancomycin and internal standard were determined by HPLC-PAD.Results: The chromatographic peak of norvancomycin and internal standard was not interfered by foreign matter.Recovery rate of 2.00,20.00,200.00 μg/mL was 90.50%,93.70%,96.40%,respectively.Accuracy in or between batches was less than 9.0% and l0.00%,respectively.The lowest detectable limit was 0.50 μg/mL and the linear range was 1.00~300.00 μg/mL.The freeze thawing of plasma was stable.Conclusion: The method was reliable and stable and it was suitable for determination of the concentration of norvancomycin in plasma.
出处 《抗感染药学》 2011年第1期36-38,共3页 Anti-infection Pharmacy
基金 盐城市科技发展项目(编号:yz2007015)
关键词 万古霉素 去甲万古霉素 高效液相色谱 vancomycin norvancomycin HPLC-PAD
  • 相关文献

参考文献4

二级参考文献28

  • 1陈利军.亚单位流感疫苗不良反应报告[J].药物不良反应杂志,2005,7(2):141-142. 被引量:6
  • 2庄贵华,颜虹,王学良,吴谦,王丽荣,高海燕.乙型肝炎疫苗无应答儿童复种五年效果观察[J].中华预防医学杂志,2006,40(1):8-12. 被引量:20
  • 3陈园生,梁晓峰,陈丽娟,贺雄,王骏,王晓军,周玉清,郭飚,林长缨,白呼群,严俊,崔钢,于竞进.中国儿童乙型肝炎疫苗预防接种效果分析[J].中国计划免疫,2006,12(2):84-87. 被引量:123
  • 4高龙明,吴建辉,亓兴中.健康教育在促进免疫规划实施过程中的作用[J].职业与健康,2006,22(12):939-940. 被引量:9
  • 5World Health Organization. WHO Guidelines on Preclinical Evaluation of Vaccines[ S]. 2005.
  • 6国家食品药品监督管理局药品审评中心.预防用生物制品临床前安全性评价技术审评一般原则[S].2005.
  • 7EMEA. Note for Guidance on Preclinical Pharmacological and Toxicological Testing of Vaccines[ S]. 1997.
  • 8FDA. Workshop on non-clinical safety evaluation of preventive vaccines: recent advances and regulatory considerations[ S]. 2002.
  • 9BALA S, WEAVER J, HASTINGS K. Clinical relevance of preclinical testing for allergic side effects[ J ]. Toxicology, 2005, 209 (2) : 195 -200.
  • 10FDA. Considerations for reproductive toxicity studies for preventive vaccines for infectious disease indications(Draft) [ S]. 2000.

共引文献54

同被引文献11

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部